ENLV vs. DARE, JAN, CASI, THTX, FBIO, VIRX, DRRX, SPRB, IPA, and NXTC
Should you be buying Enlivex Therapeutics stock or one of its competitors? The main competitors of Enlivex Therapeutics include Daré Bioscience (DARE), JanOne (JAN), CASI Pharmaceuticals (CASI), Theratechnologies (THTX), Fortress Biotech (FBIO), Viracta Therapeutics (VIRX), DURECT (DRRX), Spruce Biosciences (SPRB), ImmunoPrecise Antibodies (IPA), and NextCure (NXTC). These companies are all part of the "pharmaceutical preparations" industry.
Enlivex Therapeutics (NASDAQ:ENLV) and Daré Bioscience (NASDAQ:DARE) are both small-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their analyst recommendations, community ranking, valuation, earnings, dividends, institutional ownership, media sentiment, risk and profitability.
Enlivex Therapeutics has a beta of 1.22, suggesting that its stock price is 22% more volatile than the S&P 500. Comparatively, Daré Bioscience has a beta of 1.31, suggesting that its stock price is 31% more volatile than the S&P 500.
Enlivex Therapeutics currently has a consensus price target of $7.00, indicating a potential upside of 366.67%. Daré Bioscience has a consensus price target of $6.00, indicating a potential upside of 1,774.41%. Given Daré Bioscience's higher possible upside, analysts clearly believe Daré Bioscience is more favorable than Enlivex Therapeutics.
Daré Bioscience received 303 more outperform votes than Enlivex Therapeutics when rated by MarketBeat users. However, 77.78% of users gave Enlivex Therapeutics an outperform vote while only 73.18% of users gave Daré Bioscience an outperform vote.
Enlivex Therapeutics has higher earnings, but lower revenue than Daré Bioscience. Daré Bioscience is trading at a lower price-to-earnings ratio than Enlivex Therapeutics, indicating that it is currently the more affordable of the two stocks.
In the previous week, Daré Bioscience had 5 more articles in the media than Enlivex Therapeutics. MarketBeat recorded 6 mentions for Daré Bioscience and 1 mentions for Enlivex Therapeutics. Daré Bioscience's average media sentiment score of 0.17 beat Enlivex Therapeutics' score of 0.00 indicating that Daré Bioscience is being referred to more favorably in the news media.
Enlivex Therapeutics' return on equity of -71.00% beat Daré Bioscience's return on equity.
1.0% of Enlivex Therapeutics shares are held by institutional investors. Comparatively, 6.7% of Daré Bioscience shares are held by institutional investors. 12.3% of Enlivex Therapeutics shares are held by insiders. Comparatively, 5.3% of Daré Bioscience shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.
Summary
Daré Bioscience beats Enlivex Therapeutics on 8 of the 15 factors compared between the two stocks.
Get Enlivex Therapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for ENLV and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding ENLV and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Enlivex Therapeutics Competitors List
Related Companies and Tools
